Truist analyst David MacDonald raised the firm’s price target on HCA Healthcare to $325 from $310 and keeps a Buy rating on the shares. The company’s Q1 results were highlighted by brisk and balanced volume growth, strong margins, better adjusted earnings, and raised FY guidance, the analyst tells investors in a research note. The firm adds that it sees "plenty" of ongoing capital deployment opportunities and believes that HCA’s service line expansion should continue to fuel growth.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCA:
- HCA Healthcare price target raised to $315 from $283 at RBC Capital
- HCA Healthcare price target raised to $350 from $325 at Jefferies
- HCA Healthcare price target raised to $310 from $280 at Deutsche Bank
- HCA Healthcare price target raised to $320 from $285 at Loop Capital
- HCA Healthcare price target raised to $326 from $292 at TD Cowen
